Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
- ON THE MOVE
January 22, 2001
- JPMA Committee Calls For Deregulation to Allow Supply of Information Via Internet
January 22, 2001
- JMA to Clarify Details of Its Grand Healthcare Design
January 22, 2001
- MRs Should Take Cooperation between Medical Facilities into Account: Seminar
January 22, 2001
- Handicapped Persons to Be Given Opportunity to Become Doctors, Dentists, Nurses
January 22, 2001
- BUSINESS NEWS IN BRIEF -1-
January 22, 2001
- 2001 Meeting Schedule of the Japanese Association of Medical Sciences
January 22, 2001
- BUSINESS NEWS IN BRIEF -2-
January 22, 2001
- Celera Genomics Signs Contract with Univ. of Tokyo on Genome Database
January 22, 2001
- Daiichi Forms Alliance with MedGene
January 22, 2001
- R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…